Technology Appraisal Committee Meeting Committee C

Minutes: Confirmed

Date and Time: Wednesday 14 September 2016, 10:00 – 13:00

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:
1. Chair Professor Andrew Stevens Present for all notes
2. Kamal Balakrishnan Present for all notes
3. David Chandler Present for notes 01 to 08
4. Gail Coster Present for all notes
5. Dr Prithwiraj Das Present for all notes
6. Dr Nigel Langford Present for all notes
7. Professor Andrea Manca Present for all notes
8. Vice Chair Professor Eugene Milne Present for notes 01 to 08
9. Professor Stephen O’Brien Present for all notes
10. Dr Anna O’Neill Present for all notes
11. Professor Andrew Renehan Present for all notes
12. Dr Peter Selby Present for all notes
13. Prof Matt Stevenson Present for all notes
14. Dr Paul Tappenden Present for all notes
15. Robert Walton Present for all notes
16. Dr Judith Wardle Present for all notes

In attendance:

Dr Frances Sutcliffe Associate Director, National Institute for Health and Care Excellence Present for all notes

Stephanie Yates Project Manager, National Institute for Health and Care Excellence Present for all notes

Joanne Ekeledo Administrator, National Institute for Health and Care Excellence Present for all notes

Irina Voicechovskaja Technical Analyst, National Institute for Health and Care Excellence Present for notes 04 to 08
Notes

Welcome

1. The Vice Chair welcomed all members of the Committee and other attendees present to the meeting. The Vice Chair reviewed the agenda and timescales for the meeting, which included the appraisals of ticagrelor for secondary prevention of atherothrombotic events after myocardial infarction and apremilast for treating active psoriatic arthritis (rapid review TA372).

2. Apologies were received from Professor Kathryn Able, Dr Iain Miller, Mr Michael Chambers and Professor Rachel Elliott.

Any other Business

3. None

Appraisal of ticagrelor for secondary prevention of atherothrombotic events after myocardial infarction

Part 1 – Open session
4. The Vice Chair welcomed the invited experts: Nazish Khan and Dr Robert Storey to the meeting and they introduced themselves to the Committee.

5. The Vice Chair welcomed company representatives from AstraZeneca to the meeting.

6. The Vice Chair asked all Committee members to declare any relevant interests.
   6.1. Chair Professor Andrew Stevens, Kamal Balakrishnan, David Chandler, Gail Coster, Dr Prithwiraj Das, Dr Nigel Langford, Professor Andrea Manca, Professor Stephen O’Brien, Dr Anna O’Neill, Dr Judith Wardle, Dr Peter Selby, Prof Matt Stevenson, Dr Paul Tappenden, Robert Walton and Professor Andrew Renehan all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ticagrelor for secondary prevention of atherothrombotic events after myocardial infarction.

7. The Vice Chair asked all NICE Staff to declare any relevant interests.
   7.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ticagrelor for secondary prevention of atherothrombotic events after myocardial infarction.

8. The Vice Chair asked all other invited guests ERG and invited experts, (not including observers) to declare their relevant interests.
   8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ticagrelor for secondary prevention of atherothrombotic events after myocardial infarction.
   8.2. Dr Robert Storey declared a personal non-specific financial interest as he has received consultancy fees from AstraZeneca. It was agreed that this declaration would not prevent Dr Robert Storey from participating in this section of the meeting.

9. The Vice Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

10. The Vice Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

11. The Vice Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the
confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

12. The Vice Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

13. The Committee continued to discuss the clinical and cost effectiveness of ticagrelor for secondary prevention of atherothrombotic events after myocardial infarction.

14. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of apremilast for treating active psoriatic arthritis (rapid review TA372)

Part 1 – Open session

15. The Chair welcomed company representatives from Celgene to the meeting.

16. The Chair asked all Committee members to declare any relevant interests

16.1. Kamal Balakrishnan, Gail Coster, Dr Prithwiraj Das, Dr Nigel Langford, Professor Andrea Manca, Professor Stephen O’Brien, Dr Anna O’Neill, Dr Judith Wardle, Dr Peter Selby, Prof Matt Stevenson, Dr Paul Tappenden, Robert Walton and Professor Andrew Renehan all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of apremilast for treating active psoriatic arthritis (rapid review TA372).

16.2. Professor Matt Stevenson declared a non-personal specific financial interest as he has received payment from Biogen within the last 12 months relating to work in multiple sclerosis. Biogen has recently purchased benezepali, a biosimilar of etanercept which is a comparator in this STA.

9.2.1 It was agreed that this declaration would not prevent Professor Matt Stevenson from participating in this section of the meeting.

16.3. David Chandler is conflicted. He was the patient expert for the original appraisal and his employing organisation the Psoriasis and Psoriatic Arthritis Alliance is a listed as a stakeholders and submitted evidence in the previous appraisal

17. The Chair asked all NICE Staff to declare any relevant interests.

17.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific
18. The Chair asked the ERG to declare their relevant interests.

18.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of apremilast for treating active psoriatic arthritis (rapid review TA372).

19. The Chair introduced the key themes from the previous appraisal TA372.

20. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

21. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

22. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

23. Discussion on confidential information continued. This information was supplied by the company.

23.1. A vote was taken. The options were:
Option 1: Apremilast should be recommended as a cost-effective treatment option for people with psoriatic arthritis.
Option 2: Apremilast should not be recommended as a cost-effective treatment option for people with psoriatic arthritis.
The Committee voted for Option 1: Apremilast should be recommended as a cost-effective treatment option for people with psoriatic arthritis.
Details of the result of this discussion will be included in the confirmed version of these minutes, which will be published during the week commencing 10 October 2016 after the publication of all decisions taken at this Committee meeting.

24. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

25. Wednesday 12 October, 2016, 10:00 to 17:00 National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.